Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?

Abstract

Amendments to the European pharmacovigilance legislative framework are expected to come into force in 2011, following the adoption of the proposed amendments to Directive 2001/83/EC on the community code relating to medicinal products for human use (hereinafter referred to as the Directive) and to Regulation (EC) No. 726/2004 laying down community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (EMA) [hereinafter referred to as the Regulation]. The Regulation shall apply 18 months after publication in the Official Journal of the European Union. The amendments to the Directive and the Regulation will induce changes in the EU in terms of evaluation of risk associated with medicinal products as well as the framework on how the EU takes harmonized regulatory action on drug safety. In this review, the text agreed between the European Parliament and Council is examined and compared with the pharmacovigilance legislative framework currently in force. We argue that the new legislation has improved numerous uncertainties in current legislative framework and provides for the following: (i) clear roles, responsibilities and obligations for the key responsible parties; (ii) rationalization of EU decision making on drug safety issues in order to deliver measures that are equally and fully implemented for all relevant products across the community with a view to preventing unnecessary patient exposure to risks; (iii) strengthening medicine safety transparency and communication so that the understanding and trust of patients and health professionals in the safety of medicines will improve, as well as the penetration of key warnings; (iv) strengthening companies' pharmacovigilance systems, allowing companies to improve their systems constantly while reducing administrative burden; (v) ensuring the proactive and proportionate collection of high-quality data relevant to the safety of medicines through risk management and structured data collection in the form of Post-Authorization Safety Studies (PASS), together with rationalized single-case and periodic reporting of suspected adverse drug reactions (ADRs); (vi) involvement of stakeholders in pharmacovigilance through direct patient reporting of suspected ADRs and inclusion of patients and healthcare professionals in decision making; and (vii) simplification of the current community pharmacovigilance procedures with consequent efficiency gains for both the pharmaceutical industry and medicines regulators. For the first time, companies can be made legally liable to carry out PASS and Post-Authorization Efficacy Studies. The amendments to the Regulation and to the Directive will strengthen the European network on pharmacovigilance. A Pharmacovigilance Risk Assessment Committee (PRAC) based at the EMA will be set up, which will be responsible for all matters related to pharmacovigilance at an EU level. Three European databases will be strengthened (EudraVigilance, EudraPharm and the Europ...

A Need of Better Pharmacovigilance System in India

“…The introduction of e-commerce in the world, which provided convenience to consumers along with offers, discounts, and home-delivered products over the past decade, also led to the development of the cyber pharma drug market [16]. The last decade has seen the rise of new internet tools that have acted as important enablers of online drug markets.…”

Are patients ready to take part in the Pharmacovigilance system? a portuguese preliminary study concerning adr reporting

“…(22,23) Patient reporting is defined as "users of drugs (or their parents or carers) reporting suspected ADRs directly to a spontaneous reporting system". (24,25) However, there has been some discussion on the true value of direct reporting by patients. The perceived advantages and possible drawbacks of patient reporting of ADRs are discussed in Chapter 1.3 on the Patients' role in active surveillance.…”

“…(19) The importance of direct patient reporting has been highlighted by new European legislation on pharmacovigilance, in order to strength spontaneous reporting systems in Europe. (24) The introduction of patient reporting in pharmacovigilance indicates a change in attitude in which patient reporting is valued due to their potential to contribute with useful information on drug safety, which can be used or maximized.…”

“…Suspicions of ADR may be reported online by HCPs and patients through a platform that is currently under development in several countries: the introduction of online reporting in Portugal is being progressively implemented. (24) It also entails a revision of the definition of "adverse drug reaction" bringing to "any harmful effects caused by medications".…”

Assessing Pancreatic Cancer Risk Associated with Dipeptidyl Peptidase 4 Inhibitors: Data Mining of FDA Adverse Event Reporting System (FAERS)

“…This dilemma creates an important role for the government to step in and engage all the stakeholders of public health and proactively monitor and regulate the adverse events. The public databases hosted by the federal government serve as important information hubs to collect, evaluate and distribute health care information, which plays important role in diseases control and prevention in the changing media landscape and new information ecology [5].…”